Ren Y. et al. (2020) also noted a positive correlation between NFE2L3 expression and the aggressive behavior of liver cancer cells and EMT. This oncogenic function of NFE2L3 is likely attributed to its downregulation of cyclin D1 and TCF4 by inhibiting the Wnt/β-catenin signaling pathway. Recently, another study by this group uncovered a new role for NFE2L3 in promoting liver cancer (Ren et al., 2023). Here, NFE2L3 is linked to liver cancer.